All News
Alzheimer’s & Parkinson’s Diseases Congress-Lisbon
Poster in the 14th international conference on Alcheimer’s and Parkinson’s diseases and related neurological disorders
EUREKA Innovation Award (E!12655 MITOME) for German-Hungarian collaborative program
In the last decade, oxidative stress has emerged as a key factor in many diseases including cardiovascular diseases, cancer, atherosclerosis, diabetes, arthritis, lung, kidney, liver disease, neurodegenerative disorders, and neuropathy.
Dénes Gábor Prize to Avidin’s CEO
AVIDIN’s CEO László Puskás was recently awarded with the Dénes Gábor Prize…
Competitiveness and Excellence Co-operations (VKE)
Genetic predisposition and life style management contribute to the development of type 2 diabetes mellitus (T2DM).
Our most advanced project’s lead optimization results published
Novel 8-hydroxyquinoline pharmacophore scaffold was synthetized by Avidin’s Medicinal Pharmacolgy department which has been shown to possess a range of activities as metal chelation, enzyme inhibition, cytotoxicity
Avidin organized the fifth TAT-CF general assembly held in Budapest.
The famous Géllert Hotel was the venue selected for meeting. Thursday 14th was dedicated to a workshop session where all the partners presented the most
Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullié–Ugi Three-Component Reaction
Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullié–Ugi Three-Component Reaction (doi: 10.1021/acs.joc.7b03189) 3-9-2018 Avidin’s Medicinal Chemistry Department developed and established an innovative protocol
Our single cell protection buffer, the SingleCellProtectTM
Our single cell protection buffer, the SingleCellProtectTM was used in a recently published Nature Communication paper (doi:10.1038/s41467-017-02628-4) 3-4-2018 Previously we showed that single cells collected
Avidin joined to fourth cystic fibrosis consortium (H2020 TAT-CF) progress meeting in Mallorca (Spain)
Day one was dedicated to the 3rd TAT-CF workshop in which researchers from all partners presented their work within the H2020 project (Novel therapeutic approaches for